Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 13/20 | 0.58 |
| ▸ | DRD2 | P14416 | 8/20 | 0.58 |
| ▸ | HTR2A | P28223 | 4/20 | 0.58 |
| ▸ | PARP1 | P09874 | 3/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | HTR1D | P28221 | 9/20 | 0.56 |
| ▸ | HTR1B | P28222 | 9/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 4/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL532718 | 0.84 | PARP1 (0.80) | HTR1ADRD2HTR2APARP1SLC6A4 | |
| SCHEMBL3777754 | 0.82 | HTR1A (0.58) | HTR1ADRD2HTR2APARP1SLC6A4 | |
| SCHEMBL12346145 | 0.82 | HTR1A (0.67) | HTR1ADRD2HTR2APARP1SLC6A4 | |
| SCHEMBL5659998 | 0.80 | ALDH1A1 (0.59) | HTR1APARP1HTR1DHTR1B | |
| SCHEMBL531687 | 0.80 | DRD2 (0.66) | HTR1ADRD2HTR2APARP1SLC6A4 | |
| SCHEMBL532657 | 0.80 | DRD2 (0.81) | HTR1ADRD2HTR2APARP1SLC6A4 | |
| SCHEMBL532067 | 0.80 | DRD2 (0.66) | HTR1ADRD2HTR2APARP1SLC6A4 | |
| SCHEMBL5763201 | 0.79 | PARP1 (0.48) | DRD2PARP1DRD4 | |
| SCHEMBL5655518 | 0.79 | PARP1 (0.48) | DRD2PARP1DRD4 | |
| SCHEMBL5655775 | 0.78 | HTR2A (0.54) | HTR1ADRD2HTR2AHTR2CKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186730-B2 | Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-03-06 | — | — | US | claimed |
| EP-1392686-B1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2006-10-18 | — | — | EP | claimed |
| US-20040198755-A1 | Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-10-07 | — | — | US | claimed |
| US-7186730-B2 | Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-03-06 | — | — | US | disclosed |
| EP-1392686-B1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2006-10-18 | — | — | EP | disclosed |
| US-20040198755-A1 | Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198755-A1 | Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials | NRDC, NUCB2, ASNS | HTR1A 3274/4885DRD2 1004/4885HTR2A 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.